pipette
ESEspañol

Phase I Clinical Trial of Allogeneic Cytomegalovirus-specific T Cells in Combination with Pembrolizumab for Recurrent Glioblastoma

D. Walker, P. Martins, P. Khaledi, H. Alexander, A. Stirling, M. A. Neller, J. Kelly, V. Biggs, H. Reddiex, A. Panikkar, L. Beagley, S. Flynn, J. Raju, M. Voogt, M. Solomon, C. Smith, R. Khanna

PreprintReal-world use

In the authors' words

Purpose: Glioblastoma (GBM) remains refractory to immunotherapy due to its immunosuppressive microenvironment. Tumour-infiltrating cytomegalovirus (CMV)-specific T cells express elevated programmed cell death protein-1 (PD-1), suggesting checkpoint-mediated dysfunction may limit T-cell therapy. We evaluated the safety and immunological activity of allogeneic CMV-specific T-cell therapy (CYT-101) combined with pembrolizumab. Patients and Methods: In this phase I 3+3 dose-escalation study, recurrent GBM patients received four weekly infusions of CYT-101 followed by pembrolizumab. The primary endpoint was safety. Secondary endpoints included progression-free survival at 6 months (PFS-6), overall survival at 6 months (OS-6), and immune correlates of response. Results: CYT-101 T-cell therapy demonstrated polyfunctional activity, broad HLA restriction, potent cytolytic function, and diverse T-cell receptor repertoires. Nine patients received study treatment. No dose-limiting toxicities were observed, and the maximum tolerated dose was not reached. Only six adverse events were considered treatment-related, and no treatment-related serious adverse events, graft-versus-host disease, cytokine release syndrome, or neurotoxicity occurred. OS-6 and PFS-6 were 55% and 11%, respectively, with a median overall survival of 9.1 months. No objective clinical responses were seen. Of the nine treated participants, one had stable disease, five had progressive disease, and three were unevaluable by modified RANO criteria. Immune profiling revealed enhanced global CD4+ and CD8+ T-cell function following CYT-101 therapy, while donor-derived CYT-101 clonotypes were detected in six of nine participants, with significant T-cell repertoire remodelling. Conclusions: Allogeneic CMV-specific T-cell therapy combined with pembrolizumab was safe in recurrent GBM, supporting further evaluation of this strategy to overcome immune dysfunction in GBM.

Main resultLimitation the authors admit

Appeared: Wednesday, November 18. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.17.26367100